Estrogen Receptor Pathway: Resistance to Endocrine Therapy and New Therapeutic Approaches
Open Access
- 15 August 2006
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 12 (16), 4790-4793
- https://doi.org/10.1158/1078-0432.ccr-06-1535
Abstract
Endocrine therapy is widely accepted as the most important treatment for all patients with hormone receptor–positive breast cancer. However, despite the positive effect of endocrine therapy on clinical outcome, resistance to these drugs inevitably develops. This article reviews the problem of resistance to hormonal therapy and addresses potential approaches to overcome intrinsic or acquired mechanisms of resistance.Keywords
This publication has 27 references indexed in Scilit:
- Pharmacogenetics of Tamoxifen Biotransformation Is Associated With Clinical Outcomes of Efficacy and Hot FlashesJournal of Clinical Oncology, 2005
- Dual Inhibition of mTOR and Estrogen Receptor SignalingIn vitroInduces Cell Death in Models of Breast CancerClinical Cancer Research, 2005
- Model systems: Mechanisms involved in the loss of sensitivity to letrozoleThe Journal of Steroid Biochemistry and Molecular Biology, 2005
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- Estrogen-induced apoptosis in a breast cancer model resistant to long-term estrogen withdrawalThe Journal of Steroid Biochemistry and Molecular Biology, 2005
- A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast CancerNew England Journal of Medicine, 2004
- A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast CancerNew England Journal of Medicine, 2003
- Antiestrogen resistance in breast cancer and the role of estrogen receptor signalingOncogene, 2003
- Enhanced Estrogen Receptor (ER) α, ERBB2, and MAPK Signal Transduction Pathways Operate during the Adaptation of MCF-7 Cells to Long Term Estrogen DeprivationJournal of Biological Chemistry, 2003
- Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trialThe Lancet, 2002